Q-omics provides the consensus-scored TRPC6P profile across patient tissues and cancer cell-line models. TRPC6P expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, TRPC6P is differentially expressed in 6, with the highest sampling consensus in KIRP. Additionally, TRPC6P RNA expression shows 6,825 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight BLCA, KIRP, and STAD as cancer lineages where TRPC6P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRPC6P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRPC6P survival associations across molecular data types. TRPC6P RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRPC6P RNA expression–survival associations across cancer types. High TRPC6P expression shows unfavorable associations in LUAD, KIRC, THYM and STAD, but favorable associations in BLCA and UCS. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for TRPC6P RNA expression.
This table summarizes TRPC6P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for TRPC6P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRPC6P shows lower tumor expression in KIRP, LUSC, KICH and KIRC and higher tumor expression in PAAD and UCEC. The KIRP box plot shows higher TRPC6P RNA expression in normal versus tumor tissue (log2 FC = −0.038, t-test p = .004).
This table shows molecular features associated with TRPC6P in patient tissues and cancer cell lines. In patient samples, TRPC6P shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
